Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash & Equivalents: 2015-2024

Historic Cash & Equivalents for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $30.8 million.

  • Seres Therapeutics' Cash & Equivalents fell 28.71% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year decrease of 28.71%. This contributed to the annual value of $30.8 million for FY2024, which is 75.94% down from last year.
  • Per Seres Therapeutics' latest filing, its Cash & Equivalents stood at $30.8 million for FY2024, which was down 75.94% from $128.0 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Cash & Equivalents registered a high of $180.0 million during FY2021, and its lowest value of $30.8 million during FY2024.
  • For the 3-year period, Seres Therapeutics' Cash & Equivalents averaged around $107.3 million, with its median value being $128.0 million (2023).
  • Per our database at Business Quant, Seres Therapeutics' Cash & Equivalents surged by 78.19% in 2020 and then slumped by 75.94% in 2024.
  • Seres Therapeutics' Cash & Equivalents (Yearly) stood at $116.0 million in 2020, then soared by 55.11% to $180.0 million in 2021, then dropped by 9.43% to $163.0 million in 2022, then decreased by 21.51% to $128.0 million in 2023, then plummeted by 75.94% to $30.8 million in 2024.